News & Events
Latest News
Aravax opens IND for PVX108 Phase 2 trials and strengthens SAB
3 March 2022/by axergyAravax appoints Principal Investigators for PVX108 Phase 2 trials in United States and Australia
27 August 2021/by axergyAravax presents PVX108 Phase 1 longitudinal immunology data at EAACI 2021
13 July 2021/by axergyAravax appoints Financial Executive Thomas Ulmer to Board of Directors
1 November 2020/by axergyAravax receives positive pre-IND feedback from FDA on PVX108 Phase 2 trial plans
30 September 2019/by axergyAravax Presents Additional Positive PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019
4 June 2019/by axergyAravax to Present Additional PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019
28 May 2019/by axergyAustralian peanut therapy developer Aravax reveals positive Phase I trial results at AAAAI
25 February 2019/by axergyAravax to Present PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting
13 February 2019/by axergyAravax receives $1.9 million investment tranche from the Medical Research Commercialisation Fund
2 May 2018/by axergyCollaborator of Aravax, the Benaroya Research Institute, receives $5 million grant
29 January 2018/by axergyAravax presents encouraging preliminary Phase I safety data at the first Gordon Research Conference
13 January 2018/by axergy© Aravax
Contact Us
Email: info@aravax.com.au
Australia
Level 9, 31 Queen St, Melbourne, Victoria, 3000 Australia
Tel: +61 (0)3 9657 0700
UK
John Eccles House, Oxford Science Park
Oxford, OX4 4GP, United Kingdom
